Needham & Company Remains Positive on Dermira (DERM) Following Strong CIMPASI-2 Trial Data

October 3, 2016 2:18 PM EDT
Get Alerts DERM Hot Sheet
Price: $28.37 +0.28%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 24 | Down: 17 | New: 14
Trade DERM Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Needham & Company affirms Dermira, Inc. (Nasdaq: DERM) with a Buy rating and $46 price target after the company and UCB announced topline results from CIMPASI-2, a Phase 3, multi-center, placebo-controlled clinical trial evaluating the efficacy and safety of CIMZIA (certolizumab pegol) in adult patients with moderate-to-severe chronic plaque psoriasis.

The firm commented today, DERM began 4Q16 in style with positive results from CIMPASI-2, the first of three ph 3 pivotal trials evaluating Cimzia as a treatment for moderate-to-severe psoriasis. CIMPASI-2 successfully met co-primary endpoints (% of patients achieving PASI 75 and % of patients achieving . 2-point improvement on PGA scale) at week 16. The other two ph 3 pivotal studies (CIMPASI-1 and CIMPACT) are expected to report results by the end of 1Q17. Recall, Cimzia, a TNF inhibitor, is being developed by DERM as part of a collaboration with UCB. DERM is eligible to receive development/regulatory milestones as well as tiered sales royalties. Cimzia has shown an attractive safety/benefit profile that compares favorably to other TNF inhibitors approved for psoriasis.

For an analyst ratings summary and ratings history on Dermira click here. For more ratings news on Dermira click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Needham & Company

Add Your Comment